AVEO Pharmaceuticals, Inc. (AVEO): Drug Rejected! Let’s Rejoice?

Page 1 of 2

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘ announced yesterday that the Food and Drug Administration rejected its kidney cancer drug tivozanib.

No surprise there. The briefing documents for the advisory panel meeting expressed the FDA reviewers’ negative opinion, and tivozanib’s fate was sealed when the committee voted 13-1, recommending against approving the drug.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

What is a little surprising is that shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) jumped 8% on the news and are up another 6% today.

But only a little.

Call it a “cover the short on the news.” Not as catchy as “sell the news,” but it works in the other direction as well. After the advisory committee meeting, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock continued to fall, and the bump over the last two days puts it about where it traded after the meeting.

I certainly didn’t see anything in the rejection announcement nor today’s conference call  that would make AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) worth more after the rejection. To get tivozanib approved for kidney cancer, the FDA wants a new clinical trial since the overall survival data was confounded — to say the least — by patients crossing over from the control group to take tivozanib as well.

But AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and its partner Astellas don’t plan to fund any further trials in kidney cancer. Tivozanib is dead as a treatment for kidney cancer.

Long road
AVEO is currently trading substantially below the $192 million in cash and equivalents it had at the end of the first quarter because investors know AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has a long road ahead. It’s going to burn through all of that cash and probably substantially more before tivozanib is approved.

The drug is in two phase 2 clinical trials, one for colon cancer and another for breast cancer. The colon cancer data is due next year but is a bit of a long shot since tivozanib inhibits VEGF pathway, which hasn’t been a particularly good target in colon cancer.

More promising is the potential to treat triple negative breast cancer patients who are missing the estrogen receptor, progesterone receptor, and don’t overexpress HER2. It’s a small chunk of the breast cancer market, but there’s an unmet need, so a small gain would be meaningful. Data from that trial aren’t expected until the end of next year.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!